Evidence map›Paper›PMID 22171592›Full record

ArticleMolecular pharmaceutics2012

Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy.

Robert H Mo, Jennica L Zaro, Wei-Chiang Shen

Abstract readComparative Study
In one paragraph

Article in Molecular pharmaceutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 98 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Peptide-Assisted Nucleic Acid Delivery Systems on the Rise.International journal of molecular sciences · 2021
    Review
  17. Article
  18. Dual-Modified Liposome for Targeted and Enhanced Gene Delivery into Mice Brain.The Journal of pharmacology and experimental therapeutics · 2020
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Robert H MoDepartment of Pharmacology and Pharmaceutical Sciences, University of Southern California School of Pharmacy, Los Angeles, California 90033, USA.
Jennica L Zaro
Wei-Chiang Shen
University of Southern California · US

Funding

Membrane Transduction Peptides for Drug DeliveryR01GM070777 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SHEN, WEI-CHIANG · 2005 to 2008
$1.0M
NIGMS NIH HHS GM070777NIGMS NIH HHS R01 GM070777
6 · The paper itself

Abstract

Cell penetrating peptides (CPPs) are short strands of arginine- and/or lysine-rich peptides (<30 amino acids) that use their cationic nature for efficient intracellular accumulation. CPPs have been used for small interfering RNA (siRNA) delivery by direct complexation with the siRNA anionic phosphate backbone. During this process, however, part of the CPP cationic charges are neutralized, and the resultant loss of free positive charges may substantially compromise CPP's internalization capabilities and eventually reduce siRNA delivery efficiency. The purpose of this study was to design a novel type of polyplex for siRNA delivery to overcome the CPP neutralization issue. This novel polyplex consists of three components: siRNA, 21mer oligolysine (K21) chemically modified to incorporate CPP conjugation sites (K21-PDP), and CPP delivery moiety. The siRNA was first neutralized by cationic charges of K21-PDP to form a polyplex. Then a cationic (hexaarginine, R6) or an amphipathic (model amphipathic peptide, MAP) CPP was conjugated to the polyplex. Agarose gel shift assays indicated that the siRNA could be released from the polyplex after K21-PDP degradation or polyplex dilution. Furthermore, the total intracellular internalization of these two CPP-polyplexes was studied. Compared with R6-polyplex, MAP-polyplex exhibited 170- and 600-fold greater uptake of fluorescently labeled siRNA at 1 and 6 h post-transfection, respectively. MAP-polyplex also exhibited comparable GFP silencing effects as Lipofectamine 2000 complex in Huh7.5 cells stably transfected to express GFP-light chain 3 protein, whereas R6-polyplex did not demonstrate significant silencing activity. Further studies indicated that the K21-PDP-siRNA polyplex formation and conjugation of MAP to the polyplex were essential for siRNA polyplex uptake and gene silencing. MAP-polyplex was also shown to be unaffected by the presence of 10% FBS during transfection. In addition, MAP-polyplex uptake was dependent on vesicle formation and fusion due to 70 and 54% loss of uptake at 4 and 16 °C, respectively, compared to incubation at 37 °C. Therefore, the amphipathic CPP is a more suitable carrier moiety for delivery of siRNA polyplex.

Indexed as

RNA InterferenceAmino Acid SequenceBiological TransportCell LineCell Membrane PermeabilityCell-Penetrating PeptidesCell SurvivalDrug CarriersGreen Fluorescent ProteinsHeLa CellsHumansHydrophobic and Hydrophilic InteractionsLipidsMolecular Sequence DataPeptidesPolylysineCell-Penetrating PeptidesDrug CarriersGreen Fluorescent ProteinsLipidsLipofectamineN-succinimidyl 3-(2-pyridyldithio)propionatePeptidespolyargininePolylysineRNA, Small InterferingSuccinimides

Identifiers

PMID22171592
PMCPMC3273621
OpenAlexW2061794307

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.